Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reshape Lifesciences Q1 2024 GAAP EPS $(0.09) Beats $(0.16) Estimate, Sales $1.944M Miss $2.104M Estimate

Author: Benzinga Newsdesk | May 15, 2024 04:54pm
Reshape Lifesciences (NASDAQ:RSLS) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.16) by 43.75 percent. This is a 94.23 percent increase over losses of $(1.56) per share from the same period last year. The company reported quarterly sales of $1.944 million which missed the analyst consensus estimate of $2.104 million by 7.60 percent. This is a 15.00 percent decrease over sales of $2.287 million the same period last year.

Posted In: RSLS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist